Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

ELN 2013 Response Status Criteria: Relevance For De Novo imatinib Chronic Phase Chronic Myeloid Leukemia Patients?

Gabriel Etienne, MD, PHD, Stephanie Dulucq, MD, Axelle Lascaux, MD, Anna Schmitt, MD, Audrey Bidet, Marie-Pierre Fort, Eric Lippert, Caroline Bureau, Didier Adiko, MD, Sandrine Hayette, Josy Reiffers, MD, Franck E. Nicolini, MD PhD, Francois-Xavier Mahon, MD, PhD

Blood (2013) 122 (21): 4029.

https://doi.org/10.1182/blood.V122.21.4029.4029

Published: 2013

Journal Articles

Loss Of Major Molecular Response As a Trigger For Restarting Tyrosine Kinase Inhibitor Therapy In CP-CML Patients Who Have Stopped Imatinib After Durable Undetectable Minimal Residual Disease

Blood (2013) 122 (21): 381.

https://doi.org/10.1182/blood.V122.21.381.381

Published: 2013

Journal Articles

Long Term Follow-Up After Imatinib Cessation For Patients Indeep Molecular Response: The Update Results Of The STIM1 Study

Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, PhD, Joelle Guilhot, PhD, Francois Guilhot, MD, Françoise Huguet, Franck E. Nicolini, MD, PhD, Laurence Legros, MD, PhD, Aude Charbonnier, MD, Agnès Guerci, MD, Bruno R. Varet, MD, Gabriel Etienne, MD, PHD, Josy Reiffers, MD, Philippe Rousselot, MD, PhD

Blood (2013) 122 (21): 255.

https://doi.org/10.1182/blood.V122.21.255.255

Published: 2013

Journal Articles

Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Hagop M. Kantarjian, MD, Dong-Wook Kim, MD, Surapol Issaragrisil, MD, Richard E Clark, Josy Reiffers, MD, Franck E. Nicolini, MD, PhD, Ricardo Pasquini, Matt Kalaycio, MD, Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD, Charisse Kemp, Xiaolin Fan, PhD, Roger J. Waltzman, MD, Giuseppe Saglio, MD, Richard A. Larson, MD

Blood (2012) 120 (21): 1676.

https://doi.org/10.1182/blood.V120.21.1676.1676

Published: 2012

Journal Articles

Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy

Gabriel Etienne, MD, PHD, Nicolini E Nicolini, MD, PhD, Stéphanie Dulucq, Anna Schmitt, Sandrine Hayette, Éric Lippert, MD, PhD, Isabelle Tigaud, MD, Stephane Morisset, Stat., Caroline Bureau, Didier Adiko, Gerald Marit, MD, Josy Reiffers, MD, Francois-Xavier Mahon, MD, PhD

Blood (2012) 120 (21): 3754.

https://doi.org/10.1182/blood.V120.21.3754.3754

Published: 2012

Journal Articles

Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM Study

Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, Joelle Guilhot, Francois Guilhot, Françoise Huguet, MD, Franck E. Nicolini, MD, PhD, Laurence Legros, Aude Charbonnier, Agnès Guerci, MD, Bruno R. Varet, MD, Gabriel Etienne, MD, PhD, Josy Reiffers, MD, Philippe Rousselot, MD, PhD

Blood (2011) 118 (21): 603.

https://doi.org/10.1182/blood.V118.21.603.603

Published: 2011

Journal Articles

Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID

Andreas Hochhaus, MD, Gert Ossenkoppele, MD, PhD, Josy Reiffers, MD, Ming Yao, MD, Hirohiko Shibayama, MD, PhD, Norbert Gattermann, MD, Timothy P. Hughes, MD, MBBS, Giuseppe Saglio, MD, Richard A. Larson, MD, Albert Hoenekopp, MD, Neil J. Gallagher, MD, PhD, Richard Yu, Rick E. Blakesley, PhD, Clarisse Lobo, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 114.

https://doi.org/10.1182/blood.V118.21.114.114

Published: 2011

Journal Articles

ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD, Giuseppe Saglio, Dong-Wook Kim, MD, PhD, Saengsuree Jootar, MD, Philipp D. le Coutre, MD, Josy Reiffers, Ricardo Pasquini, MD, Clarisse Lobo, MD, Richard E. Clark, MD, Neil J. Gallagher, MD, PhD, Albert Hoenekopp, MD, Ariful Haque, Richard A. Larson, MD, Hagop M. Kantarjian, MD

Blood (2010) 116 (21): 207.

https://doi.org/10.1182/blood.V116.21.207.207

Published: 2010

Journal Articles

A More Sensitive RQ-PCR to Assess Complete Molecular Remission Does Not Allow the Prediction of Relapse After Discontinuation of Imatinib In Chronic Myeloid Leukemia.

Francois-Xavier Mahon, MD, PhD, Stéphanie Dulucq, Francois Guilhot, Laurence Legros, MD, Philippe Rousselot, MD, PhD, Coralie Belanger, Gabriel Etienne, Josy Reiffers, Delphine Rea, MD, PhD

Blood (2010) 116 (21): 2298.

https://doi.org/10.1182/blood.V116.21.2298.2298

Published: 2010

Journal Articles

Interferon Alpha Alone Is Able to Cure Chronic Myeloid Leukemia In a Small Subset of Patients Despite the Persistence of Leukemic Cells: Experience of Long Follow up After Treatment Discontinuation

Francois-Xavier Mahon, MD, PhD, Marie-Pierre Fort, Gabriel Etienne, Gerald Marit, Noel Milpied, Arnaud Pigneux, MD, PhD, Pascale Cony-Makhoul, Josy Reiffers

Blood (2010) 116 (21): 2299.

https://doi.org/10.1182/blood.V116.21.2299.2299

Published: 2010

Journal Articles

Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34 + cells from leukapheresis products autografted during the first remission

Norbert-Claude Gorin, Myriam Labopin, Josy Reiffers, Noel Milpied, Didier Blaise, Francis Witz, Theo de Witte, Giovanna Meloni, Michel Attal, Teresa Bernal, Vanderson Rocha, for the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation

Blood (2010) 116 (17): 3157–3162.

https://doi.org/10.1182/blood-2009-11-252197

Published: 2010

Journal Articles

Discontinuation of Imatinib Therapy After Achieving a Molecular Response in Chronic Myeloid Leukemia Patients.

Francois-Xavier Mahon, Delphine Rea, MD, PhD, Francois Guilhot, MD, Francoise Huguet, Franck Emmanuel Nicolini, MD, PhD, Laurence Legros, Aude Charbonnier, Agnes Guerci, Bruno R. Varet, MD, Gabriel Etienne, MD, Emilie Aton, Josy Reiffers, MD, Philippe Rousselot, MD, PhD

Blood (2009) 114 (22): 859.

https://doi.org/10.1182/blood.V114.22.859.859

Published: 2009

Journal Articles

Ex-Vivo Expanded Peripheral Blood Stem Cells (EVEC) Compared with Un Manipulated Peripheral Blood Stem Cells (PBSC) Autologous Transplantation for Multiple Myeloma: A Pair Match Analysis.

Noel-Jean Milpied, MD, Gerald Marit, Bernard Dazey, Jean-Michel Boiron, MD, PhD, Zoran Ivanovic, Carine Foucaud, Fontanet Bijou, Krimo Bouabdallah, MD, Anna Schmitt, Mathieu Sauvezie, Christian Cailliot, MD, Josy Reiffers

Blood (2009) 114 (22): 502.

https://doi.org/10.1182/blood.V114.22.502.502

Published: 2009

Journal Articles

Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients.

Blood (2009) 114 (22): 2199.

https://doi.org/10.1182/blood.V114.22.2199.2199

Published: 2009

Journal Articles

Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial

Giuseppe Saglio, Dong-Wook Kim, MD, PhD, Surapol Issaragrisil, MD, FRCP, FACP, FRCPA, FRCPath, Philipp D. le Coutre, MD, Josy Reiffers, MD, Clarisse Lobo, MD, Ricardo Pasquini, MD, Richard E. Clark, MD, Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD, Neil J. Gallagher, MD, PhD, Albert Hoenekopp, MD, Mei Dong, MD, MS, Ariful Haque, MS, Hagop M. Kantarjian, MD, Richard A. Larson, MD

Blood (2009) 114 (22): LBA-1.

https://doi.org/10.1182/blood.V114.22.LBA-1.LBA-1

Published: 2009

Journal Articles

Imatinib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients.

Carlo Gambacorti-Passerini, Dong-Wook Kim, François-Xavier Mahon, Giuseppe Saglio, Fabrizio Pane, François Guilhot, Michael W.N. Deininger, Arnon Nagler, Alessandro Rambaldi, Enrica Morra, Laura Antolini, IL-Young Kweon, Josy Reiffers, Lucia Tornaghi, Maria Grazia Valsecchi

Blood (2008) 112 (11): 1099.

https://doi.org/10.1182/blood.V112.11.1099.1099

Published: 2008

Journal Articles

Defensine Alpha1 as a New Marker of Imatinib Resistance in Chronic Myelogenous Leukemia

Gabriel Etienne, Maryse Dupouy, Claudine Chollet, Jean-Max Pasquet, Eric Lippert, Josy Reiffers, François- Xavier Mahon, Beatrice Turcq

Blood (2008) 112 (11): 3180.

https://doi.org/10.1182/blood.V112.11.3180.3180

Published: 2008

Journal Articles

Management of Chronic Myelogenous Leukemia Using Therapeutic Drug Monitoring of Imatinib: The French Experience of a Centralized Laboratory

Mathieu Molimard, Stephane Bouchet, Gabriel Etienne, Laurence Legros, Delphine Rea, Francoise Huguet, Karine Titier, Nicholas Moore, Josy Reiffers, Coralie Belanger, Francois-Xavier Mahon

Blood (2008) 112 (11): 3222.

https://doi.org/10.1182/blood.V112.11.3222.3222

Published: 2008

Journal Articles

Is It Possible to Stop Imatinib in Patients with Chronic Myeloid Leukemia? An Update from a French Pilot Study and First Results from the Multicentre « Stop Imatinib » (STIM) Study

Francois-Xavier Mahon, Francoise Huguet, MD, Francois Guilhot, MD, Laurence Legros, MD, PhD, Franck E Nicolini, MD, PhD, Aude Charbonnier, Agnes Guerci, MD, Delphine Rea, MD, PhD, Bruno R. Varet, MD, Martine Gardembas, MD, Joelle Guilhot, Gabriel Etienne, Noel-Jean Milpied, MD, PhD, Emilie Aton, Josy Reiffers, Philippe Rousselot

Blood (2008) 112 (11): 187.

https://doi.org/10.1182/blood.V112.11.187.187

Published: 2008

Journal Articles

Multidrug resistance gene ( MDR1 ) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

Stéphanie Dulucq, Stéphane Bouchet, Béatrice Turcq, Eric Lippert, Gabriel Etienne, Josy Reiffers, Mathieu Molimard, Maja Krajinovic, François-Xavier Mahon

Blood (2008) 112 (5): 2024–2027.

https://doi.org/10.1182/blood-2008-03-147744

Published: 2008

NARROW

ELN 2013 Response Status Criteria: Relevance For De Novo imatinib Chronic Phase Chronic Myeloid Leukemia Patients?

Loss Of Major Molecular Response As a Trigger For Restarting Tyrosine Kinase Inhibitor Therapy In CP-CML Patients Who Have Stopped Imatinib After Durable Undetectable Minimal Residual Disease

Long Term Follow-Up After Imatinib Cessation For Patients Indeep Molecular Response: The Update Results Of The STIM1 Study

Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy

Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM Study

ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

A More Sensitive RQ-PCR to Assess Complete Molecular Remission Does Not Allow the Prediction of Relapse After Discontinuation of Imatinib In Chronic Myeloid Leukemia.

Interferon Alpha Alone Is Able to Cure Chronic Myeloid Leukemia In a Small Subset of Patients Despite the Persistence of Leukemic Cells: Experience of Long Follow up After Treatment Discontinuation

Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34 + cells from leukapheresis products autografted during the first remission

Discontinuation of Imatinib Therapy After Achieving a Molecular Response in Chronic Myeloid Leukemia Patients.

Ex-Vivo Expanded Peripheral Blood Stem Cells (EVEC) Compared with Un Manipulated Peripheral Blood Stem Cells (PBSC) Autologous Transplantation for Multiple Myeloma: A Pair Match Analysis.

Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients.

Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial

Imatinib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients.

Defensine Alpha1 as a New Marker of Imatinib Resistance in Chronic Myelogenous Leukemia

Management of Chronic Myelogenous Leukemia Using Therapeutic Drug Monitoring of Imatinib: The French Experience of a Centralized Laboratory

Is It Possible to Stop Imatinib in Patients with Chronic Myeloid Leukemia? An Update from a French Pilot Study and First Results from the Multicentre « Stop Imatinib » (STIM) Study

Multidrug resistance gene ( MDR1 ) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only